Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NR5A2 | O00482 | 1/20 | 1.00 |
| ▸ | NR5A1 | Q13285 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | FABP3 | P05413 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | PTAFR | P25105 | 1/20 | 0.66 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.63 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235513 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Colfosceril Palmitate SCHEMBL184776 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL234621 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL233979 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL234757 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL22693933 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL17165029 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL2135188 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL233582 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL235645 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 885 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4306104-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VIRUS INFECTIONS, COMPRISING POLYMER NANODISCS | MVRIX CO LTD (KR) | 2026-03-18 | — | — | EP | claimed |
| US-12576037-B2 | Polymer-encapsulated drug particles | TONIC MEDICAL, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4106828-B1 | POLYMER-ENCAPSULATED DRUG PARTICLES | TONIC MEDICAL INC (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260062716-A1 | LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS | POPVAX PRIVATE LTD (IN) | 2026-03-05 | — | — | US | claimed |
| EP-4695401-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | Strand Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260028310-A1 | LIPID COMPOUND AND USES THEREOF | LONGUIDE BIOPHARMA CORP (CN) | 2026-01-29 | — | — | US | claimed |
| EP-4678198-A2 | POLYMER-ENCAPSULATED DRUG PARTICLES | Tonic Medical, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4659817-A2 | LIPOSOME COMPOSITION FOR USE IN PERITONEAL DIALYSIS | Versantis AG (CH) | 2025-12-10 | — | — | EP | claimed |
| EP-4062905-B1 | LIPOSOME COMPOSITION FOR USE IN PERITONEAL DIALYSIS | Versantis AG (CH) | 2025-12-03 | — | — | EP | claimed |
| WO-2010030739-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | claimed |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | US | claimed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | claimed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| WO-2009129395-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| US-20070014842-A1 | Pharmaceutical liposomal compositions | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2007-01-18 | — | — | US | claimed |
| US-20070014841-A1 | Pharmaceutical compositions | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2007-01-18 | — | — | US | claimed |
| EP-1536831-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS CONTAINING N. MENINGITIDIS DERIVED POLYPEPTIDES OR POLYNUCLEOTIDES | ID Biomedical Corporation (CA) | 2005-06-08 | — | — | EP | claimed |
| US-20040132652-A1 | Pharmaceutical compositions | SHIRE BIOCHEM INC. (CA) | 2004-07-08 | — | — | US | claimed |
| WO-2004019976-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS CONTAINING N. MENINGITIDIS DERIVED POLYPEPTIDES OR POLYNUCLEOTIDES | ID BIOMEDICAL CORPORATION (CA) | 2004-03-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | LIPA, LIPG, LIPC | SMN1; SMN2 2289/4885NR5A2 3037/4885NR5A1 1639/4885 |
| US-12576037-B2 | Polymer-encapsulated drug particles | PHOSPHO1, SGMS1, SGMS2 | SMN1; SMN2 578/4885NR5A2 3443/4885NR5A1 3606/4885 |
| US-20070014842-A1 | Pharmaceutical liposomal compositions | NGLY1, PHOSPHO1, LPXN | SMN1; SMN2 1933/4885NR5A2 2921/4885NR5A1 3363/4885 |
| US-20260028310-A1 | LIPID COMPOUND AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, LDLR, NR1H3 | SMN1; SMN2 1691/4885NR5A2 1102/4885NR5A1 1434/4885 |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | SMN1; SMN2 2586/4885NR5A2 3864/4885NR5A1 3780/4885 |
| US-20260062716-A1 | LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS | CETP, PLTP, LDLR | SMN1; SMN2 1002/4885NR5A2 2599/4885NR5A1 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.